TigecyclineThird Party Manufacturing in India

Tigecycline is a first-in-class glycylcycline antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit. It blocks the entry of amino-acyl transfer RNA molecules into the A site of the ribosome, preventing the incorporation of amino acid residues into elongating peptide chains. This bacteriostatic action halts bacterial growth and allows the immune system to clear the infection. What makes tigecycline unique is its ability to overcome the two major tetracycline-resistance mechanisms: ribosomal protection and efflux pumps. The 9-t-butyl-glycylamido side chain on its central tetracycline skeleton enables this evasion of resistance, giving it activity against multidrug-resistant organisms including MRSA, vancomycin-resistant enterococci (VRE), and extended-spectrum beta-lactamase (ESBL) producing Enterobacteriaceae. Tigecycline has a large volume of distribution with excellent tissue penetration, though plasma concentrations are relatively low, which limits its use in bloodstream infections.

Therapeutic Uses

Tigecycline is prescribed for the treatment of complicated infections in hospitalised patients:

• Complicated Skin and Skin Structure Infections: Including those caused by MRSA, Streptococcus spp., and Gram-negative pathogens
• Complicated Intra-abdominal Infections: Including peritonitis, cholangitis, appendicitis, and diverticulitis caused by ESBL-producing organisms
• Community-Acquired Pneumonia: Including infections caused by multi-drug resistant Streptococcus pneumoniae
• Polymicrobial Infections: Particularly where mixed Gram-positive, Gram-negative, and anaerobic coverage is needed
• Carbapenem-Resistant Enterobacteriaceae Infections: As a reserve agent in multi-drug resistant cases

Why Manufacturers Choose Tigecycline

Tigecycline is a high-value hospital antibiotic with growing demand as antimicrobial resistance increases globally. As a patented-origin molecule that has gone generic, it represents a significant opportunity for Indian manufacturers with sterile injectable capabilities. The lyophilized powder formulation requires WHO-GMP certified facilities and aseptic processing expertise, making it a profitable addition to a hospital injectable portfolio. Export demand from regulated markets for tigecycline is strong, particularly for institutional supply to accredited hospitals managing resistant infections.